Company / SG&A Expense
Prime Medicine, Inc. SG&A Expense History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$50.2M
FY2024
5-year range
$3.2M / $50.2M
FY2020-FY2024
Trend
+15.6%
vs FY2023
Sector context
#157 of 212
Health Care
What the data says
At $50M, Prime Medicine, Inc.'s sg&a expense ranks #56 of 212 in the Health Care sector. SG&A Expense has increased for 4 consecutive years, from $3M in FY2020 to $50M in FY2024.
Based on SEC 10-K filings.
$50M in FY2024 with a 3-year CAGR of +53.3%.
Increased from $30M to $50M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +53.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#56 of 212 in Health CareTop 26% of 212This company $50.2M Sector average $722.9M
▼
-93.1% below sector average
Key checks
Key Insights
- Prime Medicine, Inc.'s sg&a expense has grown for 4 consecutive years.
- 3-year CAGR of +53.3%, indicating consistent growth.
- In FY2024, sg&a expense increased 15.6% year-over-year.
- Ranks #157 out of 212 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.24 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $50.2M | +15.6% |
| FY2023 | $43.4M | +45.5% |
| FY2022 | $29.8M | +114.2% |
| FY2021 | $13.9M | +340.4% |
| FY2020 | $3.2M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026